CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 131 enrolled
Drug / intervention
Ultrasound contrast agent (Contrast-enhanced ultrasound) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02764801
NCT02764801Phase 3Completed
CompareCT.gov

2D and 4D Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted May 6, 2016·Updated May 6, 2025

In Brief

A Phase 3 clinical trial evaluating Ultrasound contrast agent (Contrast-enhanced ultrasound) and Logiq E9 Scanner (Contrast-enhanced ultrasound) for Hepatocellular Carcinoma and Chemoembolization, Therapeutic. Completed, enrolled 131 participants across 3 sites.

Detailed Summary

The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic resonance (MRI) or computed tomography (CT) imaging

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Chemoembolization, Therapeutic
CountriesUnited States
CollaboratorsUniversity of California, San Diego, Vanderbilt University Medical Center, National Institutes of Health (NIH), Lantheus Medical Imaging, GE Healthcare, National Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 6, 2016
Enrollment StartApr 1, 2016
Primary CompletionDec 1, 2021
Study CompletionFeb 1, 2023
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 10.2 years ago

Interventions

Ultrasound contrast agent (Contrast-enhanced ultrasound)drug

Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.

Logiq E9 Scanner (Contrast-enhanced ultrasound)device

Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.